The Hyderabad-based CSIR-Centre for Cellular and Molecular Biology on Friday announced the development of a Covid-19 vaccine candidate based on mRNA technology.
The Centre for Cellular and Molecular Biology announced development of an indigenous mRNA Covid-19 vaccine candidate.
The Hyderabad-based CSIR-Centre for Cellular and Molecular Biology on Friday announced the development of a Covid-19 vaccine candidate based on mRNA technology.
The vaccine candidate is currently in pre-clinical testing to see its efficacy to protect against the live coronavirus, according to a press release by CCMB.
The study has so far produced an efficacy of 90 per cent in preventing SARS-Cov-2, the virus that causes Covid-19 disease, from latching onto the human cell, as per the press release.
Here is all you need to know about this vaccine candidate, the mRNA technology it uses, and its claim of being indigenous.
mRNA vaccines use mRNA created in a laboratory to teach our cells how to make a protein바카라or even just a piece of a protein바카라that triggers an immune response inside our bodies, according to US Centers for Disease Control and Prevention.
There are other vaccine types as well, such as vector vaccines and inactivated vaccines.
In vector vaccines, genetic material from SARS-CoV-2 is placed in a modified version of a different virus 바카라vector바카라 and when it gets into our cells, it delivers genetic material from SARS-Cov-2 and gives our cells instructions to make copies of the Spike protein, according to the Mayo Clinic.
An inactivated whole virus vaccine, such as Covaxin, contains SARS-CoV-2 particles that have been chemically deactivated 바카라they cannot infect cells. These deactivated particles, however, still stimulate a protective immune response, according to Gavi.
The CCMB said in its press release that they observed robust response in ongoing animal studies.
Rajesh Iyer, a scientist involved in the project, said, "We observed robust immune response against SARS-CoV-2 Spike protein in mice, upon administration of two doses of the mRNA. The anti-spike antibodies generated were found to be more than 90 per cent efficient in preventing the human ACE2 receptor binding to the coronavirus."
The ACE2 receptor is what바카라s used by the 바카라spike바카라 바카라 in simpler terms, the protruding part of the virus 바카라 of SARS-CoV-2 to enter the human cell.
The CCMB press release also highlighted what makes their candidate different from Gennova Biopharmaceuticals바카라 mRNA vaccine candidate.
"The developed technology is different from mRNA vaccine being developed from Gennova Bio, which is based on self-replicating RNA," said Dr Madhusudhana Rao, the CEO of Atal Incubation Centre at CCMB.
While Pune-based Gennova are also making an mRNA coronavirus vaccine, they are collaborating with an American partner and are working on a licence-basis, which means it cannot be called completely Indian.
The CCMB calls their candidate indigenous. Their press release said, 바카라The mRNA vaccine technology so developed, is indigenous and devoid of any technology contributions from elsewhere.바카라
However, there appears to be a catch with this claim. While they say it바카라s indigenous, they have also said that they have taken the technical know-how from Moderna, the American company which has been at the forefront of mRNA vaccines.
Deccan Herald quoted Dr Rao as saying, 바카라We used the technical know-how from Moderna to establish our own mRNA vaccine technology and develop the homegrown mRNA vaccine candidate against SARS-CoV-2.바카라
Dr Rao, the CEO of the centre that worked on the vaccine, is not concerned about any challenge from Moderna.
바카라We are not expecting any challenges from Moderna. As far as we understand, their patents are not protected in India,바카라 said Dr Rao, when questioned about patent rights by Deccan Herald.